

# COVID-19 & FLU EXPRESS



*COVID-19 & Flu Express* is a weekly report produced by Surveillance Division of the Communicable Disease Branch of the Centre for Health Protection. It monitors and summarizes the latest local and global COVID-19 and influenza activities.

## Local Situation of COVID-19 Activity (as of Jul 2, 2025)

**Reporting period: Jun 22, 2025 – Jun 28, 2025 (Week 26)**

- The latest surveillance data showed that the overall local activity of COVID-19 has continuously decreased.
- The Centre for Health Protection (CHP) has been closely monitoring the local prevalence of SARS-CoV-2 variants. The latest sewage surveillance data and genetic analysis of positive respiratory specimens showed that NB.1.8.1 has become the dominating variant strains in Hong Kong. NB.1.8.1 is one of the descendant lineages of XDV, in turn a descendent of JN.1. The World Health Organization (WHO) listed NB.1.8.1 as a variant under monitoring (VUM) on May 23, 2025, and stated that NB.1.8.1 poses a low risk to global public health based on the available evidence, and that the currently approved COVID-19 vaccines are expected to be effective against NB.1.8.1, and there is no evidence to suggest that NB.1.8.1 will cause more serious diseases.
- Members of the public are advised to maintain strict personal and environmental hygiene at all times for personal protection against COVID-19 infection and prevention of the spread of the disease in the community. High-risk people (e.g. persons with underlying medical conditions or persons who are immunocompromised) should adopt additional measures to protect themselves such as wearing mask properly when going to public places. For other details, please visit the COVID-19 information page (<https://www.chp.gov.hk/en/healthtopics/content/24/102466.html>).
- Members of the public are advised to take note of the latest recommendations on the use of COVID-19 vaccines in Hong Kong to protect themselves from serious outcomes of COVID-19. High-risk priority groups are recommended to receive a dose of COVID-19 vaccine at least six months since the last dose or infection, regardless of the number of doses received previously. For more details, please visit ([https://www.chp.gov.hk/files/pdf/consensus\\_interim\\_recommendations\\_on\\_use\\_of\\_covid19\\_vaccines\\_in\\_hong\\_kong\\_17jul.pdf](https://www.chp.gov.hk/files/pdf/consensus_interim_recommendations_on_use_of_covid19_vaccines_in_hong_kong_17jul.pdf)).
- For the latest information on COVID-19 and prevention measures, please visit the thematic website of COVID-19 (<https://www.coronavirus.gov.hk/eng/index.html>).

## Laboratory surveillance for COVID-19 cases

### **Positive nucleic acid test laboratory detections for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus**

(Note: The data reported are provisional figures and subject to further revision.)

In week 26, the weekly number of newly recorded positive nucleic acid test laboratory detections for SARS-CoV-2 virus was 264 as compared to 250 in the preceding week. (Figure 1.1)

In the first 4 days of week 27 (Jun 29 – Jul 2), the daily number of newly recorded positive nucleic acid test laboratory detections for SARS-CoV-2 virus ranged from 26 to 35.

Since Jan 30, 2023, the cumulative number of positive nucleic acid test laboratory detections was 83,193 (as of Jul 2, 2025).




Figure 1.1 Weekly number of positive nucleic acid test laboratory detections for SARS-CoV-2 virus

**Positive detection rate of specimens tested positive for SARS-CoV-2 virus at the Public Health Laboratory Services Branch, Centre for Health Protection**

Among the 7,527, respiratory specimens received by the Public Health Laboratory Services Branch (PHLSB) in week 26, 302 (4.01%) were tested positive for SARS-CoV-2 virus as compared to 335 (4.47%) in the preceding week. (Figure 1.2)




Figure 1.2 Percentage of specimens tested positive for SARS-CoV-2 virus at PHLSB

## COVID-19 outbreak surveillance

(Note: The data reported are provisional figures and subject to further revision.)

In week 26, 5 COVID-19 outbreaks occurring in schools/institutions were recorded (affecting 27 persons), as compared to 8 outbreaks recorded in the previous week (affecting 48 persons). (Figure 1.3)

In the first 4 days of week 27 (Jun 29 – Jul 2), 0 COVID-19 outbreaks occurring in schools/institutions were recorded (affecting 0 persons).




Figure 1.3 COVID-19 outbreaks in schools/institutions

Type of institutions	Week 25	Week 26	First 4 days of week 27 (Jun 29 – Jul 2)
Child care centre/ kindergarten (CCC/KG)	1	0	0
Primary school (PS)	0	0	0
Secondary school (SS)	0	0	0
Residential care home for the elderly	6	5	0
Residential care home for persons with disabilities	0	0	0
Others	1	0	0
<i>Total number of outbreaks</i>	8	5	0
<i>Total number of persons affected</i>	48	27	0

## Surveillance of severe and fatal COVID-19 cases

(Note: The data reported are provisional figures and subject to further revision.)

In week 26, the weekly number of severe COVID-19 cases including deaths with cause of death preliminarily assessed to be related to COVID-19 was 6 as compared to 6 in the preceding week. (Figure 1.4)

Since Jan 30, 2023, the cumulative number of fatal cases with cause of death preliminarily assessed to be related to COVID-19 was 1,488 (as of Jun 28, 2025).




Figure 1.4 Weekly number of severe COVID-19 cases including deaths

Note: Severe and fatal cases are recorded according to their initial reporting dates.

## Sewage surveillance of SARS-CoV-2 virus

In week 26, the 7-day geometric mean per capita viral load of SARS-CoV-2 virus from sewage surveillance was around 120,000 copy/L as compared to around 190,000 copy/L in the preceding week. (Figure 1.5)




Figure 1.5 7-day geometric mean per capita viral load of SARS-CoV-2 virus from sewage surveillance since May 1, 2022

*Note: The dotted line refers to the temporary sewage sampling suspension for a safety review by the Drainage Services Department.*

## COVID-19 surveillance among sentinel general out-patient clinics and sentinel private medical practitioner clinics

In week 26, the average consultation rate for COVID-19 among sentinel general out-patient clinics (GOPC) and sentinel private medical practitioner clinics were 10.8 (Figure 1.6) and 11.0 (Figure 1.7) COVID-19 cases per 1,000 consultations, respectively.




Figure 1.6 Average consultation rate of COVID-19 cases in GOPC




Figure 1.7 Average consultation rate of COVID-19 cases in private medical practitioner clinics

## Surveillance on SARS-CoV-2 variants

Currently, WHO is monitoring one variant of interest (VOI), which is JN.1, and six VUMs, which are KP.3, KP.3.1.1, LP.8.1, NB.1.8.1, XEC and XFG. CHP conducts surveillance on SARS-CoV-2 variants from sewage samples. The latest surveillance data (as of Jun 25, 2025) showed that NB.1.8.1 (one of the descendant lineages of XDV) is the most prevalent variant, comprising 83.6% of all characterised specimens. (Figure 1.8)




Figure 1.8 Estimated proportion of variants among sewage samples

\*Including JN.1 and its descendant lineages, except those individually specified elsewhere in the table

#Those SARS-CoV-2 variants not classified as VOIs/VUMs by WHO at the time of reporting. In the latest surveillance, all of them belongs to XDV and its descendant lineages except NB.1.8.1.

Note: KP.3, KP.3.1.1, LP.8.1, XEC and XFG are the descendant lineages of JN.1

CHP also conducted genetic characterisation on reported severe and fatal cases of COVID-19 between Jun 18 and Jul 1, 2025. The results showed that NB.1.8.1 was the most prevalent variant, comprising 90% of all characterised specimens.

Besides, CHP conducted genetic characterisation for the specimens obtained from some non-severe cases of COVID-19 during the same period. The results showed that NB.1.8.1 was the most prevalent variant, comprising 95% of all characterised specimens.



## Global situation of COVID-19 activity

- According to the WHO, global SARS-CoV-2 activity was generally low, except in the South-East Asia Region and the Europe Region, where elevated activity was reported.
- The COVID-19 activity gradually decreases in some of the neighborhood regions, while it has remained stable in North America and increased slightly in Europe.
  - ◆ In Mainland China (week ending Jun 22, 2025), the percentage of specimens tested positive for SARS-CoV-2 has shown a continuous downward trend, with the rate observed in southern provinces generally being higher than that in northern provinces. The predominant variant was NB.1.8.1 recently.
  - ◆ In Taiwan region (week ending Jun 21, 2025), the COVID-19 activity continued to decrease, with the number of COVID-19 outpatient and emergency visits declining compared to the previous week; however, the number of severe cases and deaths remained high. The predominant variant was NB.1.8.1.
  - ◆ In Japan (week ending Jun 22, 2025), the average number of reported COVID-19 cases per sentinel site increased to 1.00 from 0.90 in the preceding week. The predominant variant was NB.1.8.1.
  - ◆ In South Korea (week ending Jun 21, 2025), the weekly detection rate for SARS-CoV-2 was 9.6% compared to 9.9% in the preceding week. The predominant variant was NB.1.8.1.
  - ◆ In Thailand (week ending Jun 28, 2025), the COVID-19 activity has begun to subside from the peak after the Songkran Festival.
  - ◆ In Singapore (week ending Jun 21, 2025), the positivity rate for COVID-19 among acute respiratory infection (ARI) samples in the community was 16% compared to 15% in the preceding week.
  - ◆ In the United States (week ending Jun 21, 2025), the percent positivity of COVID-19 was 3.0% compared to 2.9% in the preceding week. The predominant variant was NB.1.8.1.
  - ◆ In Canada (week ending Jun 14, 2025), all indicators of COVID-19 activity are at or near the lowest levels reported this season. Percentage of tests positive for COVID-19 is low and stable at 2.8%. The predominant variant was NB.1.8.1.
  - ◆ In the United Kingdom (week ending Jun 15, 2025), COVID-19 activity increased slightly across most indicators and was at baseline levels. COVID-19 PCR positivity in hospital settings increased slightly to 6.6% as compared with 6.2% in the preceding week. The predominant variant were LP.8.1.1 and XFG.
  - ◆ In Europe (week ending Jun 22, 2025), SARS-CoV-2 positivity from sentinel specimens was 9% compared to 10% in the prior week. The predominant variant were XFG and LP.8.1.1.
  - ◆ In Australia (fortnight ending Jun 15, 2025), test positivity for SARS-CoV-2 has increased this fortnight. The predominant variant was NB.1.8.1.

### Sources:

Information have been extracted from the following sources when updates are available: [World Health Organization](#), [Chinese Center for Disease Control and Prevention](#), [Taiwan Centers for Disease Control](#), [Japan Ministry of Health](#), [Korean Disease Control and Prevention Agency](#), [Thailand Department of Disease Control](#), [Singapore Communicable Diseases Agency](#), [United States Centers for Disease Control and Prevention](#), [Public Health Agency of Canada](#), [UK Health Security Agency](#), [European Centre for Disease Prevention and Control \(ECDC\)](#) and [WHO Regional Office for Europe \(WHO Euro\)](#), and [Australian Department of Health and Aged Care](#).

## Local Situation of Influenza Activity (as of Jul 2, 2025)

**Reporting period: Jun 22 – 28, 2025 (Week 26)**

- The latest surveillance data showed that the local influenza activity remained at low level despite a slight increase in the past two weeks.
- Influenza can cause serious illnesses in high-risk individuals and even healthy persons. Given that seasonal influenza vaccines are safe and effective, all persons aged 6 months or above except those with known contraindications are recommended to receive influenza vaccine to protect themselves against seasonal influenza and its complications, as well as related hospitalisations and deaths.
- 2024/25 Seasonal Influenza Vaccination Programmes, including the Seasonal Influenza Vaccination School Outreach Programme and the Residential Care Home Vaccination Programme (RVP), has been launched on September 26, 2024. The public may visit the CHP's Vaccination Schemes page for more details of the vaccination programmes (<https://www.chp.gov.hk/en/features/17980.html>).
- Apart from getting influenza vaccination, members of the public should always maintain good personal and environmental hygiene.
- For the latest information on seasonal influenza and its prevention, please visit the Centre for Health Protection's Seasonal Influenza page ([http://www.chp.gov.hk/en/view\\_content/14843.html](http://www.chp.gov.hk/en/view_content/14843.html)).

### Influenza-like-illness surveillance among sentinel general out-patient clinics and sentinel private medical practitioner clinics, 2021-25

In week 26, the average consultation rate for influenza-like illness (ILI) among sentinel general outpatient clinics (GOPC) was 4.8 ILI cases per 1,000 consultations, which was higher than 4.0 recorded in the previous week (Figure 2.1, left). The average consultation rate for ILI among sentinel private medical practitioner (PMP) clinics was 33.6 ILI cases per 1,000 consultations, which was higher than 30.7 recorded in the previous week (Figure 2.1, right).




Figure 2.1 ILI consultation rates at sentinel GOPC (left) and PMP clinics (right), 2021-25

## Laboratory surveillance, 2021-25

Among the 8,005 respiratory specimens received in week 26, 149 (1.86%) were tested positive for seasonal influenza A or B viruses. Among the subtyped influenza detections, there were 73 (50%) influenza A(H1), 31 (21%) influenza A(H3) and 41 (28%) influenza B viruses. The positive percentage (1.86%) was below the baseline threshold of 4.94% but was higher than 1.44% recorded in the previous week (Figure 2.2).




Figure 2.2 Percentage of respiratory specimens tested positive for influenza viruses, 2021-25 (upper: overall positive percentage, lower: positive percentage by subtypes)

[Notes: The Centre for Health Protection (CHP) of the Department of Health closely monitors the local seasonal influenza activity through a series of surveillance systems. Among them, the CHP sets threshold levels for two important influenza indicators, including the positive percentage of influenza detections among respiratory specimens and the admission rate of patients diagnosed with influenza in public hospitals. These threshold levels are calculated statistically based on data collected for both indicators in the past years during non-season periods. Using these thresholds, the CHP assesses the current local situation of seasonal influenza with higher accuracy and determines whether Hong Kong enters influenza season. The CHP annually reviews and analyses the latest surveillance data, and updates these threshold levels where appropriate. The sensitivity of the surveillance system is enhanced with the updated thresholds of positive percentage of influenza detection and admission rate of higher coherence.]

Remarks: Some specimens may contain vaccine strains from people with recent history of receiving live-attenuated influenza vaccine

\* Including 7,527 specimens received by Public Health Laboratory Services Branch, Centre for Health Protection and 478 specimens received by the Hospital Authority

## Surveillance of oseltamivir resistant influenza A and B viruses

- Public Health Laboratory Services Branch, Centre for Health Protection tests influenza virus isolates obtained from cell culture for antiviral susceptibility.
- In May 2025, there were no new reports of oseltamivir (Tamiflu) resistant influenza A(H1) virus.
- For the results of previous months, please refer to the following webpage: <https://www.chp.gov.hk/en/statistics/data/10/641/695/7088.html>
- Low detection rates of oseltamivir (Tamiflu) resistant influenza A and B viruses from latest surveillance data of overseas countries (less than 5%).
- CHP will continue laboratory surveillance on oseltamivir (Tamiflu) resistance of influenza viruses to monitor the trend.

## Influenza-like illness outbreak surveillance, 2021-25

In week 26, 9 ILI outbreaks occurring in schools/institutions were recorded (affecting 39 persons), as compared to 0 outbreak recorded in the previous week (Figure 2.3). In the first 4 days of week 27 (Jun 29 to Jul 2), 7 ILI outbreaks in schools/institutions were recorded (affecting 29 persons).




Figure 2.3 ILI outbreaks in schools/institutions, 2021-25

Type of institutions	Week 25	Week 26	First 4 days of week 27 (Jun 29 – Jul 2)
Child care centre/ kindergarten (CCC/KG)	0	2	0
Primary school (PS)	0	5	4
Secondary school (SS)	0	1	0
Residential care home for the elderly	0	1	2
Residential care home for persons with disabilities	0	0	1
Others	0	0	0
<i>Total number of outbreaks</i>	0	9	7
<i>Total number of persons affected</i>	0	39	29

## Influenza-associated hospital admission rates in public hospitals based on discharge coding, 2021-25

In week 26, the overall admission rates in public hospitals with principal diagnosis of influenza was 0.09 (per 10,000 population), which was below the baseline threshold of 0.27 but was higher than 0.08 recorded in the previous week. The influenza-associated admission rates for persons aged 0-5 years, 6-11 years, 12-17 years, 18-49 years, 50-64 years and 65 years or above were 0.46, 0.30, 0.11, 0.05, 0.04 and 0.10 cases (per 10,000 people in the age group) respectively, as compared to 0.34, 0.43, 0.00, 0.03, 0.04 and 0.12 cases in the previous week (Figure 2.4).




Figure 2.4 Influenza-associated hospital admission rates, 2021-25 (upper: overall rate, lower: rates by age groups)

[Notes: The Centre for Health Protection (CHP) of the Department of Health closely monitors the local seasonal influenza activity through a series of surveillance systems. Among them, the CHP sets threshold levels for two important influenza indicators, including the positive percentage of influenza detections among respiratory specimens and the admission rate of patients diagnosed with influenza in public hospitals. These threshold levels are calculated statistically based on data collected for both indicators in the past years during non-season periods. Using these thresholds, the CHP assesses the current local situation of seasonal influenza with higher accuracy and determines whether Hong Kong enters influenza season. The CHP annually reviews and analyses the latest surveillance data, and updates these threshold levels where appropriate. The sensitivity of the surveillance system is enhanced with the updated thresholds of positive percentage of influenza detection and admission rate of higher coherence.]

### Rate of ILI syndrome group in accident and emergency departments, 2021-25<sup>#</sup>

In week 26, the rate of the ILI syndrome group in the accident and emergency departments (AEDs) was 114.5 (per 1,000 coded cases), which was lower than the rate of 114.6 in the previous week (Figure 2.5).

<sup>#</sup>Note: This syndrome group includes codes related to ILI such as influenza, upper respiratory tract infection, fever, cough, throat pain, and pneumonia.




Figure 2.5 Rate of ILI syndrome group in AEDs, 2021-25

### Fever surveillance at sentinel child care centres/ kindergartens, 2021-25

In week 26, 0.43% of children in the sentinel child care centres / kindergartens (CCCs/KGs) had fever (38°C or above) as compared to 0.66% recorded in the previous week (Figure 2.6).




Figure 2.6 Percentage of children with fever at sentinel CCCs/KGs, 2021-25

### Fever surveillance at sentinel residential care homes for the elderly, 2021-25

In week 26, 0.07% of residents in the sentinel residential care homes for the elderly (RCHes) had fever (38°C or above), compared to 0.07% recorded in the previous week (Figure 2.7).




Figure 2.7 Percentage of residents with fever at sentinel RCHes, 2021-25

### Influenza-like illness surveillance among sentinel Chinese medicine practitioners, 2021-25

In week 26, the average consultation rate for ILI among Chinese medicine practitioners (CMPs) was 0.91 ILI cases per 1,000 consultations as compared to 0.73 recorded in the previous week (Figure 2.8).




Figure 2.8 ILI consultation rate at sentinel CMPs, 2021-25



## Surveillance of severe influenza cases

(Note: The data reported are provisional figures and subject to further revision.)

### **Surveillance for intensive care unit (ICU) admission/death with laboratory confirmation of influenza among adult patients (Aged 18 years or above)**

Since 2018, the Centre for Health Protection (CHP) has collaborated with the Hospital Authority and private hospitals to monitor ICU admissions and deaths with laboratory confirmation of influenza among adult patients regularly. For surveillance purpose, the cases refer to laboratory-confirmed influenza patients who required ICU admission or died within the same admission of influenza infection. Their causes of ICU admission or death may be due to other acute medical conditions or underlying diseases.

- In week 26, 1 adult case of ICU admission/death with laboratory confirmation of influenza (including 1 death) was recorded, as compared to 6 cases (including 6 deaths) in the previous week.

Week	Influenza type			
	A(H1)	A(H3)	B	A (pending subtype)
Week 25	5	0	1	0
Week 26	0	1	0	0

### **Surveillance of severe paediatric influenza-associated complication/death (Aged below 18 years)**

- In week 26 and the first 4 days of week 27 (Jun 29 to Jul 2), there were no cases of severe paediatric influenza-associated complication/death.
- In 2025, 11 paediatric cases of severe influenza-associated complication/death were recorded, in which none of them were fatal (as of Jul 2).




Figure 2.9 Weekly number of severe influenza cases by age groups, 2021-25 (the percentage positive for influenza viruses in Figure 2.2 is also shown in this graph)

## Global Situation of Influenza Activity

In the Northern Hemisphere, influenza activities continued to decline or remained stable in most countries. In the Southern Hemisphere, influenza activities continued to increase (data up to Jun 15, 2025).

- In the United States (week ending Jun 21, 2025), the seasonal influenza activity was low. The percentage of specimens tested positive for influenza was 1.2%.
- In Canada (week ending Jun 14, 2025), influenza activity was at interseasonal level. Influenza positivity continued to decrease to 1.0%.
- In the United Kingdom (week ending Jun 15, 2025), influenza activity was at baseline levels. Influenza positivity in England remained stable at 0.7% as compared with 0.7% in preceding week.
- In Europe (week ending Jun 22, 2025), indicators of influenza activity returned to interseasonal levels. Influenza positivity from sentinel specimens was at 2%, which was below the 10% epidemic threshold.
- In Mainland China (week ending Jun 22, 2025), the percentage of specimens tested positive for influenza in southern and northern provinces were at low levels, with 0.9% and 1.1% in week 25 respectively.
- In South Korea (week ending Jun 21, 2025), the weekly ILI rate decreased to 5.1 per 1,000 out-patient visits, which was below the seasonal epidemic threshold of 8.6.
- In Australia (fortnight ending Jun 15, 2025), the number of influenza cases was moderate in the last fortnight; however, case numbers have not been increasing as steeply as in previous years or the five year average. Most influenza notifications were influenza A, followed by influenza B.
- In New Zealand (week ending Jun 22, 2025), the national ILI rate slightly decreased in week 25. Nine (23.1%) out of 39 sentinel samples were tested positive for influenza in week 24. Influenza A(H1) and B viruses co-circulated.

### Sources:

Information have been extracted from the following sources when updates are available: [World Health Organization](#), [United States Centers for Disease Control and Prevention](#), [Public Health Agency of Canada](#), [UK Health Security Agency](#), [European Centre for Disease Prevention and Control \(ECDC\)](#) and [WHO Regional Office for Europe \(WHO Euro\)](#), [Chinese National Influenza Center](#), [Korean Disease Control and Prevention Agency](#) and [Australian Department of Health and Aged Care](#) and [New Zealand Ministry of Health](#).